Emergências e Terapia Intensiva

NEW Research—In suspected #COVID19 in the community, doxycycline was not associated with clinically meaningful reductions in time to recovery or hospital admissions or deaths, and should not be used as a routine treatment

Read the PRINCIPLE trial here https://t.co/Osw1hZLCaY pic.twitter.com/Q3VrpAO9cm

— The Lancet Respiratory Medicine (@LancetRespirMed) July 28, 2021

M-A | Prevalência global da intenção de deixar o trabalho entre enfermeiros de terapia intensiva – “27% dos enfermeiros de terapia intensiva têm intenção de mudar de área.”

2 Ago, 2021 | 17:22h

Global prevalence of turnover intention among intensive care nurses: A meta-analysis – Nursing in Critical Care (link para o resumo – $ para o texto completo)

Comentário no Twitter

Every fourth ICU nurse has the intention to leave, according to a meta-analysis incl 23,140 nurses from 23 countries in 18 studies (2007-2020), even higher in younger nurses.
Authors recommend social support, better working conditions, and evaluationshttps://t.co/f19iD0GLPL pic.twitter.com/NIM9nrVKiL

— Peter Nydahl (@NydahlPeter) July 28, 2021

Análise das evidências | Piperacilina-tazobactam é segura em pacientes alérgicos à penicilina?

2 Ago, 2021 | 17:20h

Is piperacillin-tazobactam safe in patients with penicillin allergy? – PulmCrit

COVID-19 e mucormicose: a tempestade perfeita.

2 Ago, 2021 | 16:56h

COVID-19 and mucormycosis superinfection: the perfect storm – Infection

Conteúdos relacionados:

ECMM/ISHAM recommendations for clinical management of COVID -19 associated mucormycosis in low- and middle-income countries.

The “Black Fungus” in India: The Emerging Syndemic of COVID-19–Associated Mucormycosis – careful use of antibiotics and corticosteroids and closely monitoring blood glucose levels are some of the strategies suggested by the authors.

Multicenter Epidemiologic Study of Coronavirus Disease–Associated Mucormycosis, India – Uncontrolled diabetes mellitus was the most common underlying disease; improper glucocorticoid use was independently associated with the disease.

Opinion | “Doctors have been blamed for the rise in black fungus in India, but the COVID treatment guidelines could be contributing” – improper use of antibiotics and higher than usual doses of corticosteroids may be contributing to the emergence of mucormycosis and other fungal co-infections.

What is mucormycosis, the fungal infection affecting COVID patients in India?

[Preprint] The Emergence of COVID-19 Associated Mucormycosis: Analysis of Cases From 18 Countries.

Mucormycosis: The ‘black fungus’ maiming Covid patients in India

Global Guideline for the Diagnosis and Management of Mucormycosis

Estudo randomizado | Antibioticoterapia por 7 dias é tão boa quanto por 14 dias para homens com infecção de trato urinário que estejam sem febre.

2 Ago, 2021 | 16:51h

Effect of 7 vs 14 Days of Antibiotic Therapy on Resolution of Symptoms Among Afebrile Men With Urinary Tract Infection: A Randomized Clinical Trial – JAMA (gratuito por tempo limitado)

Editorial: Shorter Courses of Antibiotics for Urinary Tract Infection in Men (gratuito por tempo limitado)

Comentário: Study Supports Shorter Antibiotic Course for Afebrile Men With UTI – MPR

Comentário no Twitter

Practice changing study, we always consider UTI in men as a complicated disease and we usually treat for longer time sometimes even more than 14 days, this study found that you can treat for shorter time ~7 days #IDTwitter #medtwitter #TwitteRx https://t.co/LSWYTAG15y

— Antibiotic Steward 🆔🇵🇸 Bassam Ghanem (@ABsteward) July 27, 2021

Relatório do CDC | Transmissão de Candida auris pan-resistente em instituições de cuidados em saúde.

2 Ago, 2021 | 16:46h

Notes from the Field: Transmission of Pan-Resistant and Echinocandin-Resistant Candida auris in Health Care Facilities ― Texas and the District of Columbia, January–April 2021 – CDC Morbidity and Mortality Weekly Report

Comentários:

CDC reports two outbreaks of pan-resistant Candida auris – CIDRAP

U.S. sees first cases of dangerous fungus resistant to all drugs in untreated people – STAT

Conteúdos relacionados:

Case reports: Multidrug-resistant Candida auris infections in critically ill Covid-19 patients

Candida auris: A Review of Recommendations for Detection and Control in Healthcare Settings

Global Epidemiology of Emerging Candida Auris (revisões e comentários sobre o tema)

The superbug Candida auris is giving rise to warnings — and big questions – STAT

Candida Auris – “A Mysterious Infection, Spanning the Globe in a Climate of Secrecy” (revisões e comentários sobre o tema)

Comentários no Twitter

⛔Breaking⛔
For the 1st time ever, CDC researchers reported 5 cases of people carrying pan-resistant
Candida.auris "3 Washington,D.C.2:Texas" resistant to all classes of antifungal drugs none had been treated with antifungal drugs prior to the diagnosishttps://t.co/uzj6wGI6Ps

— Antibiotic Steward 🆔🇵🇸 Bassam Ghanem (@ABsteward) July 22, 2021

Candida auris is a fungus that spreads easily and can cause dangerous infections. New evidence is emerging that cases of C. auris resistant to all classes of antifungal drugs are spreading in health care settings. Read the report: https://t.co/olhWJZM4r5. #Cauris pic.twitter.com/1MgMSLsKyc

— CDC (@CDCgov) July 23, 2021

M-A de estudos randomizados | Oxigenoterapia conservadora para pacientes criticamente doentes.

28 Jul, 2021 | 09:43h

Conservative oxygen therapy for critically ill patients: a meta-analysis of randomized controlled trials – Journal of Intensive Care

Diretriz NICE | Infecção por Clostridioides difficile infection: prescrição de antibióticos.

27 Jul, 2021 | 10:22h

Clostridioides difficile infection: antimicrobial prescribing – National Institute for Health and Care Excellence

Infográfico: Clostridioides difficile infection: antimicrobial prescribing

Conteúdos Relacionados:

IDSA 2021 focused update guidelines on the management of Clostridioides difficile infection in adults.

ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections.

Prevention of Clostridioides difficile in hospitals: A position paper of the International Society for Infectious Diseases

Review | My Treatment Approach to Clostridioides difficile Infection.

Novidades na terapia intensiva: sustentabilidade ambiental.

Revisão sistemática | Não há evidências que suportem o uso de ivermectina no tratamento ou na prevenção de COVID-19.

Estudo randomizado PRINCIPLE | Doxiciclina não melhora os desfechos de pacientes ambulatoriais com suspeita de COVID-19.